Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Halobetasol/lidocaine - Citius Pharmaceuticals

Next Previous
Search
Drug Profile

Halobetasol/lidocaine - Citius Pharmaceuticals

Alternative Names: CITI-002; Halo-Lido; Lidocaine/halobetasol

Latest Information Update: 15 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Citius Pharmaceuticals LLC
  • Developer Citius Pharmaceuticals Inc
  • Class Acetanilides; Anti-inflammatories; Antiallergics; Antipsoriatics; Class Ib antiarrhythmics; Corticosteroids; Local anaesthetics; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Phospholipase A2 inhibitors; Sodium channel antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemorrhoids

Most Recent Events

  • 10 Jul 2024 Citius Pharmaceuticals completes an end of phase II b meeting with the US FDA
  • 02 Jan 2024 Citius Pharmaceuticals plans an end of phase II meeting with the US FDA for regulatory and clinical development program for CITI 002 in early 2024
  • 20 Jun 2023 Efficacy and adverse events data from a phase IIb trial in Haemorrhoids released by Citius Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top